Instrument Inactif

Autres langues RAMM Pharma Corp. OTC Markets

Actions

RAMMF

CA75150G1046

Produits pharmaceutiques

Autres langues

30/06	RAMM Pharma Corp. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2026
02/04	RAMM Pharma Corp. Reports Earnings Results for the First Quarter Ended January 31, 2026
05/03	RAMM Pharma Corp. Reports Earnings Results for the Full Year Ended October 31, 2025
05/03	RAMM Pharma Corp. Auditor Raises 'Going Concern' Doubt
13/11	RAMM Pharma Corp. Receives Minority Shareholder Approval for Proposed Investment Transaction with The Global South S.A.S.
07/11	RAMM Pharma Corp. Provides Additional Disclosure in Connection with its Upcoming Special Meeting of Shareholders
22/10/25	RAMM Pharma Corp. Provides Update on Canada post strike and mailing of the Company´s meeting materials
27/09/25	RAMM Pharma Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2025
27/06/25	RAMM Pharma Corp. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2025
31/05/25	Early Warning Press Release Respecting the Acquisition of Common Shares of RAMM PHARMA Corp.
30/05/25	Jack Burnett of RAMM Pharma Corp. acquired additional 3.91% stake in RAMM Pharma Corp. from Armando Blankleider for CAD 46.6 million.
01/04/25	RAMM Pharma Corp. Reports Earnings Results for the First Quarter Ended January 31, 2025
04/03/25	Tranche Update on RAMM Pharma Corp.'s Equity Buyback Plan announced on September 5, 2023.
04/03/25	RAMM Pharma Corp. Reports Earnings Results for the Full Year Ended October 31, 2024
04/03/25	RAMM Pharma Corp. Auditor Raises 'Going Concern' Doubt
21/01/25	RAMM Pharma Explores Sale of its Canapar Unit
21/01/25	RAMM Pharma Corp. Provides Update on Canapar
11/12/24	RAMM Pharma Corp. Provides Update on Litigation
27/09/24	Tranche Update on RAMM Pharma Corp.'s Equity Buyback Plan announced on September 5, 2023.
27/09/24	RAMM Pharma Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2024
04/09/24	RAMM Pharma Corp.'s Equity Buyback announced on September 5, 2023, has expired with 3,011,000 shares, representing 2.52% for CAD 0.17 million.
29/06/24	Tranche Update on RAMM Pharma Corp.'s Equity Buyback Plan announced on September 5, 2023.
29/06/24	RAMM Pharma Corp. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2024
21/05/24	RAMM Pharma Corp. Provides Update on Litigation
29/03/24	Tranche Update on RAMM Pharma Corp.'s Equity Buyback Plan announced on September 5, 2023.